Vinod H. Thourani

Vinod H. Thourani

Auto-generated profile, based on publicly available information

Vinod H. Thourani

Piedmont Heart Institute, Atlanta, Georgia, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
VTVinod H. Thourani
Vinod H. Thourani
LBLevi Bonnell
Levi Bonnell
MBMoritz C. Wyler von Ballmoos
Moritz C. Wyler von Ballmoos
JMJ. Hunter Mehaffey
J. Hunter Mehaffey
MBMichael Bowdish
Michael Bowdish
VBVinay Badhwar
Vinay Badhwar

3 June 2022 in Structural Heart
Verified
Journal Article
Open access
FEFateme Esmailie
Fateme Esmailie
ARAtefeh Razavi
Atefeh Razavi
BYBreandan Yeats
Breandan Yeats
SSSri Krishna Sivakumar
Sri Krishna Sivakumar
HCHuang Chen
Huang Chen
LDLakshmi Prasad Dasi
Lakshmi Prasad Dasi
Transcatheter aortic valve replacement (TAVR) is a rapidly growing field enabling replacement of diseased aortic valves without the need for open heart surgery. However, due to the nature of the procedure and nonremoval of the diseased tissue, there are rates of complications ranging from tissue rupture and coronary obstruction to paravalvular leak, valve thrombosis, and permanent pacemaker implantation. In recent years, computational modeling has shown a great deal of promise in its capabilities to understand the biomechanical implications of TAVR as well as help preoperatively predict risks inherent to device–patient-specific anatomy biomechanical interaction. This includes intricate replication of stent and leaflet designs and tested and validated simulated deployments with structural and fluid mechanical simulations. This review outlines current biomechanical understanding of device-related complications from TAVR and related predictive strategies using computational modeling. An outlook on future modeling strategies highlighting reduced order modeling which could significantly reduce the high time and cost that are required for computational prediction of TAVR outcomes is presented in this review paper. A summary of current commercial/in-development software is presented in the final section.

29 August 2025 in European Heart Journal
Verified
Journal Article
Closed access
PLPhilipp Lurz
Philipp Lurz
RHRebecca T Hahn
Rebecca T Hahn
SKSusheel Kodali
Susheel Kodali
RMRaj Makkar
Raj Makkar
RSRahul P Sharma
Rahul P Sharma
VTVinod H Thourani
Vinod H Thourani
Background and Aims: The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods: The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results: One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions: Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.

18 October 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
NBNeel M. Butala
Neel M. Butala
DWDavid A. Wood
David A. Wood
HLHaiyan Li
Haiyan Li
KCKhaja Chinnakondepalli
Khaja Chinnakondepalli
SLSandra B. Lauck
Sandra B. Lauck
OIon behalf of the 3M-TAVR Investigators
on behalf of the 3M-TAVR Investigators
Background: The 3M-TAVR trial (3M-Transcatheter Aortic Valve Replacement) demonstrated the feasibility and safety of next-day hospital discharge after transfemoral TAVR with implementation of a minimalist pathway. However, the economic impact of this approach is unknown. Therefore, we evaluated costs for patients undergoing minimalist TAVR compared with conventional TAVR. Methods: We used propensity matching to compare resource utilization and costs (from a US health care system perspective) for patients in the 3M-TAVR trial with those for transfemoral TAVR patients enrolled in the contemporaneous S3i trial (PARTNER SAPIEN-3 Intermediate Risk). Procedural costs were estimated using measured resource utilization for both groups. For the S3i group, all other costs through 30-day follow-up were assessed by linkage with Medicare claims; for 3M, these costs were assessed using regression models derived from S3i cost and resource utilization data. Results: After 1:1 propensity matching, 351 pairs were included in our study (mean age 82, mean Society of Thoracic Surgery risk score 5.3%). There were no differences in death, stroke, or rehospitalization between the 3M-TAVR and S3i groups through 30-day follow-up. Index hospitalization costs were $10 843/patient lower in the 3M-TAVR cohort, driven by reductions in procedure duration, anesthesia costs, and length of stay. Between discharge and 30 days, costs were similar for the 2 groups such that cumulative 30-day costs were $11 305/patient lower in the 3M-TAVR cohort compared with the S3i cohort ($49 425 versus $60 729, 95% CI for difference $9378 to $13 138; P <0.001). Conclusions: Compared with conventional transfemoral TAVR, use of a minimalist pathway in intermediate-risk patients was associated with similar clinical outcomes and substantial in-hospital cost savings, which were sustained through 30 days. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02287662.

1 November 2021 in Structural Heart
Verified
Journal Article
Open access
PDF file
VTVinod H. Thourani
Vinod H. Thourani
JBJ. Matthew Brennan
J. Matthew Brennan
JEJ. James Edelman
J. James Edelman
QCQinyu Chen
Qinyu Chen
IBIsabel J. Boero
Isabel J. Boero
SKSusheel K. Kodali
Susheel K. Kodali
Background Symptomatic severe aortic regurgitation (ssAR) is a Class I recommendation for surgical aortic valve replacement (SAVR). We sought to evaluate the practice patterns and drivers of ssAR patients receiving SAVR treatment. Methods Using a US dataset of de-identified electronic health records, we identified integrated delivery network patients diagnosed with ssAR between 2008 and 2016 with ≥2 symptom-related notes (heart failure, angina, dyspnea, pre-syncope, or syncope) within six months prior to diagnosis. Results From a final cohort of 4,608 ssAR patients, 25.7% of ssAR patients underwent SAVR within 1 year of diagnosis; mortality at 1 year was 9% after SAVR, and 24% for those untreated. Using multilevel, multivariable, cause-specific models, women and patients >80 years old were found to be treated significantly less likely [hazard ratios (HR) 0.79 (95% confidence interval [CI]: 0.69–0.90) and 0.28 (0.22–0.37), respectively]. Patients with concomitant moderate/severe aortic stenosis [1.70 (1.43–2.03)], bicuspid aortic valve disease [1.33 (1.13–1.56)], and endocarditis [2.70 (1.04–3.57)] were more likely to be treated. Using multivariable Cox proportional hazard models, ssAR patients managed by cardiologists in the highest SAVR treatment rate tertile had a 23% lower risk of 1-year mortality compared to patients managed by cardiologists in the lowest SAVR treatment rate tertile [0.77 (0.60–0.98)]. Conclusions We identified significant disparities in the treatment of ssAR patients, specifically women, older patients, and patients managed by cardiologists with a lower SAVR treatment rate. These gaps should be addressed to level the quality of care delivered to all ssAR patients.

1 October 2022 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
VTVinod H. Thourani
Vinod H. Thourani
JBJames M. Brennan
James M. Brennan
JEJ. James Edelman
J. James Edelman
DTDylan Thibault
Dylan Thibault
OJOliver K. Jawitz
Oliver K. Jawitz
MMMichael J. Mack
Michael J. Mack